| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Age disparities in lung cancer survival in New Zealand: The role of patient and clinical factors
|
Pilleron, Sophie
|
|
|
157 |
C |
p. 92-99
|
artikel
|
| 2 |
A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer
|
Fung, A.S.
|
|
|
157 |
C |
p. 21-29
|
artikel
|
| 3 |
A reply to “managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy”
|
Ceresoli, Giovanni L.
|
|
|
157 |
C |
p. 165-166
|
artikel
|
| 4 |
CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials
|
Chintala, Navin K.
|
|
|
157 |
C |
p. 48-59
|
artikel
|
| 5 |
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)
|
Wislez, Marie
|
|
|
157 |
C |
p. 124-130
|
artikel
|
| 6 |
Contents
|
|
|
|
157 |
C |
p. v-vi
|
artikel
|
| 7 |
Corrigendum to “Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)” [Lung Cancer 152 (2021) 174–184]
|
Griesinger, Frank
|
|
|
157 |
C |
p. 167
|
artikel
|
| 8 |
Development of unenhanced CT-based imaging signature for BAP1 mutation status prediction in malignant pleural mesothelioma: Consideration of 2D and 3D segmentation
|
Xie, Xiao-Jie
|
|
|
157 |
C |
p. 30-39
|
artikel
|
| 9 |
Discontinuous stereotactic body radiotherapy schedule increases overall survival in early-stage non-small cell lung cancer
|
Duvergé, L.
|
|
|
157 |
C |
p. 100-108
|
artikel
|
| 10 |
Editorial Board
|
|
|
|
157 |
C |
p. iii
|
artikel
|
| 11 |
Erratum to “30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease” [Lung Cancer 122 (2018) 165–170]
|
Osti, M.F.
|
|
|
157 |
C |
p. 168
|
artikel
|
| 12 |
FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow
|
Rogasch, Julian M.M.
|
|
|
157 |
C |
p. 66-74
|
artikel
|
| 13 |
Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis
|
Lei, Haike
|
|
|
157 |
C |
p. 60-65
|
artikel
|
| 14 |
High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung
|
Sugimoto, Akira
|
|
|
157 |
C |
p. 1-8
|
artikel
|
| 15 |
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era
|
Passiglia, Francesco
|
|
|
157 |
C |
p. 85-91
|
artikel
|
| 16 |
Impact of COVID-19 on the management of patients with thoracic cancers in a tertiary referral center
|
Basse, Clémence
|
|
|
157 |
C |
p. 79-84
|
artikel
|
| 17 |
Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases
|
Yang, Yufan
|
|
|
157 |
C |
p. 116-123
|
artikel
|
| 18 |
Lung cancer patients with COVID-19 in Spain: GRAVID study
|
Provencio, Mariano
|
|
|
157 |
C |
p. 109-115
|
artikel
|
| 19 |
Lymph Node Dissection in Thymoma: Is it worth it?
|
Clermidy, Hugo
|
|
|
157 |
C |
p. 156-162
|
artikel
|
| 20 |
Management of thymoma associated autoimmune pure red cell aplasia: Case report and systematic review of the literature
|
Lesire, Bastien
|
|
|
157 |
C |
p. 131-146
|
artikel
|
| 21 |
Managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy
|
Barsky, Andrew R.
|
|
|
157 |
C |
p. 163-164
|
artikel
|
| 22 |
Practical demonstration of time bias with administration of adjuvant therapy in lung cancer
|
Newman, Neil B.
|
|
|
157 |
C |
p. 75-78
|
artikel
|
| 23 |
Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ
|
Talcott, Wesley J.
|
|
|
157 |
C |
p. 17-20
|
artikel
|
| 24 |
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer
|
Popat, Sanjay
|
|
|
157 |
C |
p. 9-16
|
artikel
|
| 25 |
Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis
|
Zhu, Viola W.
|
|
|
157 |
C |
p. 147-155
|
artikel
|
| 26 |
Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada
|
Debieuvre, Didier
|
|
|
157 |
C |
p. 40-47
|
artikel
|
Tijdschrift beschrijving